|
|
Blood, 15 March 2008, Vol. 111, No. 6, pp. 3236-3244.
Prepublished online as a Blood First Edition Paper on December 20, 2007; DOI 10.1182/blood-2007-10-117812.
 Previous Article | Table of Contents | Next Article 
RED CELLS
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure
Yoji Andrew Minamishima1,
Javid Moslehi1,2,
Nabeel Bardeesy3,
Darragh Cullen2,
Roderick T. Bronson4, and
William G. Kaelin, Jr1,5
1 Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
2 Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;
3 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA;
4 Rodent Histopathology Core, Department of Pathology, Harvard Medical School, Boston, MA; and
5 Howard Hughes Medical Institute, Chevy Chase, MD
Pharmacologic activation of the heterodimeric HIF transcription factor appears promising as a strategy to treat diseases, such as anemia, myocardial infarction, and stroke, in which tissue hypoxia is a prominent feature. HIF accumulation is normally linked to oxygen availability because an oxygen-dependent posttranslational modification (prolyl hydroxylation) marks the HIF subunit for polyubiquitination and destruction. Three enzymes (PHD1, PHD2, and PHD3) capable of catalyzing this reaction have been identified, although PHD2 (also called Egln1) appears to be the primary HIF prolyl hydroxylase in cell culture experiments. We found that conditional inactivation of PHD2 in mice is sufficient to activate a subset of HIF target genes, including erythropoietin, leading to striking increases in red blood cell production. Mice lacking PHD2 exhibit premature mortality associated with marked venous congestion and dilated cardiomyopathy. The latter is likely the result of hyperviscosity syndrome and volume overload, although a direct effect of chronic, high-level HIF stimulation on cardiac myocytes cannot be excluded.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. A. Garcia
Aiming Straight for the Heart: Prolyl Hydroxylases Set the BAR
Sci. Signal.,
November 10, 2009;
2(96):
pe70 - pe70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. A. Minamishima, J. Moslehi, R. F. Padera, R. T. Bronson, R. Liao, and W. G. Kaelin Jr.
A Feedback Loop Involving the Phd3 Prolyl Hydroxylase Tunes the Mammalian Hypoxic Response In Vivo
Mol. Cell. Biol.,
November 1, 2009;
29(21):
5729 - 5741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Barth, F. Edlich, U. Berchner-Pfannschmidt, S. Gneuss, G. Jahreis, P. A. Hasgall, J. Fandrey, R. H. Wenger, and G. Camenisch
Hypoxia-inducible Factor Prolyl-4-hydroxylase PHD2 Protein Abundance Depends on Integral Membrane Anchoring of FKBP38
J. Biol. Chem.,
August 21, 2009;
284(34):
23046 - 23058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Xie, K. Xiao, E. J. Whalen, M. T. Forrester, R. S. Freeman, G. Fong, S. P. Gygi, R. J. Lefkowitz, and J. S. Stamler
Oxygen-Regulated {beta}2-Adrenergic Receptor Hydroxylation by EGLN3 and Ubiquitylation by pVHL
Sci. Signal.,
July 7, 2009;
2(78):
ra33 - ra33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nakayama, J. Qi, and Z. Ronai
The Ubiquitin Ligase Siah2 and the Hypoxia Response
Mol. Cancer Res.,
April 1, 2009;
7(4):
443 - 451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ladroue, R. Carcenac, M. Leporrier, S. Gad, C. Le Hello, F. Galateau-Salle, J. Feunteun, J. Pouyssegur, S. Richard, and B. Gardie
PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma
N. Engl. J. Med.,
December 18, 2008;
359(25):
2685 - 2692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
